Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HWK-016
- Development stage
- Phase 1
- Lead developer
- Whitehawk Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HWK-016 is an antibody-drug conjugate (ADC) designed to target the membrane-bound portion of **MUC16**, a glycoprotein frequently overexpressed in ovarian and other female-origin malignancies. By focusing on the membrane-bound fraction, HWK-016 aims to avoid the “antigen sink” problem that hampered earlier MUC16-targeted therapies. Its mechanism of action involves delivery of a DNA topoisomerase I inhibitor payload to cancer cells expressing MUC16, leading to DNA damage and cell death. HWK-016 represents a next-generation ADC aimed at improving targeting precision and reducing off-target toxicity, addressing significant unmet needs in ovarian cancer. The drug was originally developed by WuXi Biologics and is further developed by Whitehawk Therapeutics, following in-licensing. As of July 2025, HWK-016 is in preclinical development, with IND submission planned for late 2025 and initial focus on ovarian cancer[1][3][4][5][7][9][10].
- Brand names
- HWK-016HWK016HWK 016
- Other names
- HWK-016HWK016HWK 016
02
Targets
MUC16 (Mucin-16)
Beyond the preview
Go deeper on HWK-016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HWK-016.